Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting, stable LDL-C ≥ 160 mg/dL~* Fasting, stable triglyceride \< 400 mg/dL~* BMI between 22 and 35 kg/m2, inclusive~* Females must be of non-child bearing potential~* Males of reproductive potential must agree to practice effective contraception throughout the study and for 3 months following infusion~Exclusion Criteria:~* Clinically significant endocrine, hematologic, renal, hepatic, pulmonary, uncontrolled psychiatric, or neurologic disease~* Cancer within 5 years prior to screening~* History of congestive heart failure or chronic heart failure~* Uncontrolled cardiac arrhythmias~* History of coronary heart disease~* Clinically significant abnormal baseline ECG~* History of additional risk factors for torsades de pointes~* Hepatitis B, C, or HIV positive~* Current diagnosis or known history of liver disease~* A marked baseline prolongation of QT/QTc interval~* Known history of fibromyalgia, myopathy, myositis, rhabdomyolysis, any unexplained muscle pain, or a creatine phosphokinase (CPK) \>3 x upper limit of normal (ULN) at screening~* Alanine aminotransferase, AST, GGT, or total bilirubin \>2 x ULN at screening~* Serum creatinine \> 1.5 mg/dL~* Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg on 2 occasions during screening~* Concomitant use of medications that prolongs the QT/QTc interval~* Treatment with lipid lowering therapy within 30 days prior to screening~* Use of investigational drug within 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- PRO-040201 (Type: EXPERIMENTAL): PRO-040201 with placebo control in each cohort
- Placebo (Type: PLACEBO_COMPARATOR): PRO-040201 with placebo control in each cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).